研究表明,pemprolizumab改善了头部和颈部癌症患者的治疗结果,有可能成为新的护理标准。 Study shows pembrolizumab improves outcomes in head and neck cancer patients, potentially becoming new standard of care.

一项新的研究表明,在头部和颈部癌手术之前、期间和之后添加免疫疗法药物囊肿,可大大改善患者的治疗结果,包括延长存活时间,避免癌症复发和肿瘤收缩率提高。 A new study shows that adding immunotherapy drug pembrolizumab before, during, and after surgery for head and neck cancer significantly improves patient outcomes, including longer survival without cancer recurrence and higher rates of tumor shrinkage. 由Dana-Farber和华盛顿大学研究人员牵头的第三阶段临床试验没有发现新的副作用,并表明这一方法可成为新的护理标准。 The Phase III clinical trial, led by researchers from Dana-Farber and Washington University, found no new side effects and suggests this approach could become the new standard of care. 美国食品和药物管理局正在审查这种方案的潜在批准. The U.S. FDA is reviewing the potential approval of this regimen.